Assenagon Asset Management S.A. Raises Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Assenagon Asset Management S.A. grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 244.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,389,847 shares of the company's stock after purchasing an additional 985,845 shares during the period. Assenagon Asset Management S.A. owned about 0.12% of Teva Pharmaceutical Industries worth $25,045,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. IFM Investors Pty Ltd increased its position in shares of Teva Pharmaceutical Industries by 3.7% during the third quarter. IFM Investors Pty Ltd now owns 231,028 shares of the company's stock worth $4,163,000 after purchasing an additional 8,285 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 7.2% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 310,116 shares of the company's stock worth $5,588,000 after acquiring an additional 20,837 shares during the last quarter. X Square Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3.0% during the third quarter. X Square Capital LLC now owns 220,163 shares of the company's stock valued at $3,967,000 after acquiring an additional 6,500 shares in the last quarter. Private Advisor Group LLC raised its position in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Private Advisor Group LLC now owns 26,104 shares of the company's stock valued at $470,000 after purchasing an additional 2,990 shares during the last quarter. Finally, Signaturefd LLC grew its position in Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company's stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 1.9 %

NYSE:TEVA traded down $0.35 during trading hours on Friday, hitting $17.90. The company's stock had a trading volume of 5,125,753 shares, compared to its average volume of 9,355,061. The stock has a fifty day moving average of $18.01 and a 200-day moving average of $16.78. The stock has a market capitalization of $20.27 billion, a P/E ratio of -43.66, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 52-week low of $8.10 and a 52-week high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Argus upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, Barclays upped their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.67.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.